T. Rowe Price Investment Management, Inc. Erasca, Inc. Transaction History
T. Rowe Price Investment Management, Inc.
- $164 Billion
- Q3 2025
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Erasca, Inc. stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 20,231,906 shares of ERAS stock, worth $52.2 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
20,231,906
Previous 20,332,161
0.49%
Holding current value
$52.2 Million
Previous $25.8 Million
70.81%
% of portfolio
0.03%
Previous 0.02%
Shares
6 transactions
Others Institutions Holding ERAS
# of Institutions
155Shares Held
213MCall Options Held
281KPut Options Held
32K-
Frazier Life Sciences Management, L.P. Menlo Park, CA22.7MShares$58.6 Million2.1% of portfolio
-
Vr Adviser, LLC New York, NY17.9MShares$46.1 Million5.91% of portfolio
-
Logos Global Management LP San Francisco, CA15.2MShares$39.1 Million3.82% of portfolio
-
Suvretta Capital Management, LLC New York, NY14.5MShares$37.4 Million0.95% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY13.6MShares$35 Million0.95% of portfolio
About Erasca, Inc.
- Ticker ERAS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 122,147,000
- Market Cap $315M
- Description
- Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...